Abstract | Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent remission. Allogeneic HSCT reduces relapse, but nonrelapse mortality and morbidity might counterbalance this beneficial effect. Here, we review recent studies reporting new disease-specific prognostic markers, in addition to allogeneic-HSCT-related risk factors, which can be assessed at specific time points during treatment. We propose risk assessment as a dynamic process during treatment, incorporating both disease-related and transplant-related factors for the decision to proceed either to allogeneic HSCT or to apply a nontransplant strategy. We suggest that allogeneic HSCT might be favoured if the projected disease-free survival is expected to improve by at least 10% based on an individual's risk assessment. The approach requires initial disease risk assessment, identifying a sibling or unrelated donor soon after diagnosis and the incorporation of time-dependent risk factors, all within the context of an integrated therapeutic management approach.
Introduction
Myeloablative allogeneic haematopoietic stem-cell transplan tation (HSCT) from a human leukocyte antigen (HLA)-identical sibling donor is generally recom mended for patients with acute myeloid leukaemia (AML, Box 1) who are in their first complete remission and who do not have a 'favourable risk' genetic profile. [1] [2] [3] [4] [5] [6] [7] [8] [9] Although allogeneic HSCT offers a strong antileukaemic effect, the benefit of the transplant in terms of overall survival can be compromised by nonrelapse mortality. As a consequence, allogeneic HSCT can result in a substantial improvement of disease-free survival (DFS) and improved overall survival in a particular group of patients, but also in reduced survival rates in other patients, despite considerably reducing the likelihood of relapse. Thus, it is important to assess the most significant variables that influence relapse and the parameters predicting nonrelapse mortality at diagnosis and at later time points during treatment ( Figure 1 ).
Several questions must be repeatedly addressed for the individual patient during this process. Having achieved remission, to what extent does allogeneic HSCT reduce relapse as compared with an alternative consolidation strategy (such as chemotherapy or autologous HSCT) in this particular type of leukaemia? How do allogeneic HSCT and the alternative consolidation strategy compare with respect to their effects on nonrelapse mortality and morbidities? If the risks of nonrelapse mortality and relapse are combined for a given patient, what percentage of long-term DFS can be projected for the patient? What are the opportunities for salvage and outcome estimates after relapse? Combining the answers to these questions might yield an estimate of the extent the composite end point DFS can be improved and whether quality of life will be compromised. In this article, we discuss studies of new disease-specific prognostic markers for AML as well as allogeneic-HSCT-related risk factors that should be identified at specific time points during treatment. We propose a dynamic risk assessment strategy during treatment, which integrates both disease-related and transplantrelated risks, to assist in the decision making for an individual patient to proceed with either allogeneic HSCT or a nontransplant approach. The aim of allogeneic HSCT is to improve DFS by at least 10%, which is based on earlier recommendations from large meta-analyses.
4-6 Thus, our integrated approach deviates from a 'one size fits all' strategy and will possibly result in an increasingly tailored approach for each individual patient.
Risk factors for AML
Cytogenetic analysis has enabled AML to be distinguished into categories that are associated with
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widely different prognoses and risks of relapse. Three cyto genetic prognostic categories ('favourable' , 'intermediate' and 'poor') have long been used. However, cytogenetic risk classification is continuously being refined, 10 incorporating new categories such as the so-called monosomal karyotype category, which is associated with a very poor outcome and currently used by several cooperative AML study groups. 11 As a detailed review of cytogenetic abnormalities is already available, current cytogenetic abnormalities to be taken into account are summarized in Table 1 and presented according to prognosis. The listing is based largely on a recent summary by Grimwade et al. 10 and the European LeukemiaNet recommendations. 12 Although patients with therapy-related AML (t-AML) might present frequently with abnormal karyotypes, t-AML is also independently associated with an adverse prognosis, possibly because of the cumulative toxicity of the preceding cancer treatment(s). 13, 14 Several large donor versus no-donor studies and their meta-analyses have shown that allogeneic HSCT using a sibling donor results in superior DFS and overall survival rates in patients with poor-risk AML profiles who are in their first complete remission. A meta-analysis by Yanada et al. 4 5 The reduction of relapse was estimated at approximately 50% (hazard ratio [HR] = 0.46, 95% CI 0.37-0.57, P <0.001), derived from an intention-totreat analysis. Although relapse was also considerably reduced in patients with favourable-risk profiles who had a risk of relapse <35%, these patients did not benefit from myeloablative allogeneic HSCT in terms of overall survival because a nonrelapse mortality of approximately 20% attenuated the beneficial effect of allogeneic HSCT. These results were confirmed and extended in a larger meta-analysis by Koreth et al., 6 which included 18 prospective studies of patients with AML in their first complete remission. Although these older studies were confined to younger patients receiving grafts from sibling donors, 5,6 the results indicated that myeloablative allogeneic HSCT might be recommended more generally for patients in their first complete remission who have intermediate-risk or poor-risk cytogenetic subtypes of AML, but not for patients with cytogenetically favourable subtypes of AML where the relapse probability is ≤35%. The latter group applies to most patients with the so-called core binding factor leukaemias-AML t(8;21) and AML inv(16)/t(16;16). Meanwhile, continued study of allogeneic HSCT in intermediate-risk AML is warranted because of a continuous trend of progressively improved survival following autologous HSCT and/or chemotherapy as consolidation therapy.
15-18
The role of allogeneic HSCT in the new 'very poorrisk' monosomal karyotype subcategory has recently also been addressed. [19] [20] [21] [22] Although the rate of relapse after allogeneic HSCT in patients in this category is high, a long-term survival rate of 20% was reported. 19, 20 Furthermore, virtually no surviving patients were noted among those in complete remission who received chemotherapy alone or autologous transplantation. Strikingly, the relative reduction of relapse by allo geneic HSCT might not differ from what can be observed in other cytogenetic subtypes of AML. 20 This observation indicates that the immunotherapeutic effect of allogeneic HSCT is exerted similarly among different AML categories and depends on alloreactive HLA (minor and major) differences rather than on the leukaemia subcategory. Further benefit from the immunotherapeutic graft-versus-leukaemia (GVL) effect might possibly be obtained by continued chemotherapy after allogeneic HSCT with agents such as 5-azacytidine, which is currently being explored as a post-transplant chemotherapy to enable ongoing GVL effects.
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Earlier recommendations on how to apply allogeneic HSCT were based on donor versus no-donor studies that were designed to avoid bias by applying a so-called Mendelian (genetic) randomization to approximate statistical randomization. [4] [5] [6] With the increased availability of unrelated donors, the analytical strategy of sibling donor versus no-donor comparisons can only be applied to historical cohorts because an increasing Box 1 | Acute myeloid leukaemia: disease and treatment AML is a heterogeneous neoplastic disorder of the bone marrow characterized by an abnormal proliferation and differentiation of myelopoietic precursors. AML presents at all ages, but is predominantly a disease of the elderly (median age approximately 70 years). The most recent WHO classification (2008) is based on underlying cytogenetic and molecular genetic abnormalities that categorize clinicopathological entities with distinctive and highly variable outcome. 145 Induction chemotherapy-consisting of one or two cycles of Ara-C therapyresults in complete remission rates of around 80% in the young and 60-80% in the elderly. Consolidation with intermediate or high-dose Ara-C is applied to reduce relapse. 12 Unfortunately, AML is characterized by a high propensity to relapse; this is most probably because of the persistence of leukaemia stem cells. The most effective therapy to prevent relapse is allogeneic HSCT. The donor stem-cell graft is infused following conditioning therapy to prevent rejection. The procedure relies on a strong antileukaemic effect (the so-called graft-versusleukaemia effect) exerted by donor T cells. However, alloreactive T cells can also harm healthy tissues, a complication known as graft-versus-host disease, which might predispose patients to treatment-related mortality. By reducing the intensity of the conditioning regimen, mortality can be reduced, which has enabled HSCT to be considered in elderly patients. Those patients not qualifying for HSCT can receive an additional cycle of chemotherapy, but prolonged maintenance treatment is usually not applied. Currently, 40-50% of adults below the age of 60 are cured, whereas 5-year survival in the elderly is <15%. 8, 12 Large differences between the various genetic risk groups have become evident in recent years. The identification of specific genetic abnormalities has paved the way for targeted therapy in AML. Currently, a number of targeted therapies are being tested in clinical studies worldwide.
Abbreviations: AML, acute myeloid leukaemia; Ara-C, anthracycline and cytosine-arabinoside; HSCT, haematopoietic stem-cell transplantation.
number of patients can actually receive an allograft from an unrelated donor. Thus, other statistical methods have to be applied, such as landmark analysis and the use of multivariable models, which include allogeneic HSCT as a time-dependent covariate.
17,24-28 The latter approach (using allogeneic HSCT as a time-dependent covariate) is based in a univariable setting on the method originally developed by Mantel and Byar, 24 but currently extended to a multivariable setting similar to the Andersen-Gill model. 27 These methods are increasingly applied in leukaemia studies to correct for selection bias.
17,20,26,29
Molecular markers
The majority of patients with AML in their first complete remission have an intermediate-risk profile. 5, 6, 12 Although most of these leukaemias lack a specific prognostically relevant karyotypic abnormality, molecular genetic markers (such as gene mutations and dysregulated gene expression) can be identified in the majority of patients and can be associated with a specific prognosis (Table 1) . 30, 31 Approximately 50% of patients with cytogenetically normal AML can carry a mutation in the nucleophosmin gene (NPM1). 32 The prognostic value of the presence of an NPM1 mutation seemed to depend on the presence of internal tandem duplication (ITD) in the receptor-type tyrosine-protein kinase FLT3 gene (FLT3-ITD). [33] [34] [35] [36] Myeloid leukaemia characterized by an NPM1 mutation without FLT3-ITD exhibited a morefavourable prognosis with relapse rates <30%. A German study evaluating allogeneic HSCT in molecularly defined subgroups of cytogenetically normal patients with AML showed that patients with an NPM1 mutation without FLT3-ITD did not benefit from allo geneic HSCT because of counterbalancing nonrelapse mortality, which is very similar to what had been observed in cytogenetically favourable subgroups of patients.
5,6
However, allogeneic HSCT was associated with better survival in patients with the FLT3-ITD mutation, although the relapse rate after transplant might be somewhat higher (30-40%) to that observed in patients with intermediate-risk profiles. 9, 37, 38 Additionally, the molecular subtype of AML characterized by biallelic mutation of CEBPA (the gene that encodes CCAAT/enhancer-binding protein α) was associ ated with a more favourable prognosis than patients without this mutation; in particular, the subtype of AML characterized by a biallelic CEBPA mutation is associated with a low risk of relapse.
39-43 Thus, it seems reasonable to also withhold myeloablative allogeneic HSCT in this category of patients with AML. Although new molecular abnormalities associated with a better prognosis have been put forward, 44-48 validation in indepen dent cohorts of patients with mature follow up data is scarce. However, a continued and intensive effort to optimize the molecular characterization of the different AML subtypes is currently ongoing with special emphasis on patients with AML who lack a specific cytogenetic marker. Recent studies have shown that mutational analy sis might enable the identification of patients both with favourable and poor-risk profiles among a group that had initially been defined as intermediaterisk by cytogenetics. 44, 45 Although mutated IDH seems to be associated with a better prognosis, especially if the mutation co-occurs with mutations of NPM1, mutations in the genes TET2, MLL and DNMT3A were found to be associated with adverse prognoses. 44, 45 In particular, DNMT3A mutations were shown to be associated with poor outcomes independent of age and/or the presence of FLT3-ITD or NPM1 mutations. However, these findings need confirmation by other large cooperative groups because data on the prognostic value of IDH1 and IDH2 are contro versial. [46] [47] [48] In addition, new molecular markers have been identified that specifically relate to patients with very poor-risk AML profiles, characterized by a very high risk of relapse after attainment of first complete remission (Table 1 ). This category, for instance, includes patients with AML who overexpress the gene encoding the MDS1 and EVI1 complex locus protein EVI1 (also known as ecotropic viral integration site 1, Evi-1).
49-51
The outcomes of younger patients with Evi-1 overexpression are dismal, but recipients in their first complete remission who proceeded to allogeneic HSCT were suggested to benefit from such an approach.
51

Response and residual disease
Apart from cytogenetic and molecular prognostic markers that are identified at diagnosis, a number of variables to be monitored during induction and consolidation therapy might offer additional prog nostic information. Such information, in turn, might affect the decision whether or not to proceed to allogeneic HSCT. These variables include time to complete remission, number of blasts appearing early after induction therapy and quantified minimal residual disease (MRD) after induction or consolidation (Table 1) . 52 Different groups have shown that quantified levels of MRD relate to outcome and risk of relapse in patients in their first complete remission, although prospective validation studies are largely lacking. A study from Italy addressed the question whether multicolour flow cytometry (MFC) applied after induction and consolidation would identify patients with a low risk of relapse (defined as a <30-35% probability), as is possible for patients with favourable-risk profiles, based on cytogenetics and/or molecular techniques prior to the start of treatment. 53 By combining the results of MFC obtained after induction and consoli dation, a new subgroup of patients was identified who had a favourable prognosis and for whom post poning allogeneic HSCT might be preferred until eventual relapse. One important caveat in those studies, however, is the effect of allogeneic HSCT itself in this 'new' group. If the majority of patients in the 'good-risk' subgroup actually received an allogeneic HSCT and benefitted from that modality, omitting treatment in the future might be hazardous without having shown favourable outcomes in a substantial number of patients who did not proceed to allogeneic HSCT. In principle, this caveat applies to all studies claiming to identify a new subgroup of so-called good-risk patients, which necessitates the prospective evaluation of risk-adapted treatment, including decisions based on MRD. Furthermore, the presence or absence of MRD before transplantation can provide important prognostic information. 54 Thus, the presence of MRD prior to consolidation might identify a subgroup of patients with a particularly high risk of relapse who would thereby qualify for allogeneic HSCT, even if otherwise classified in a prognostically favourable subgroup.
MRD can be quantified by MFC and PCR, including quantitative assays. PCR-based monitoring in patients with cytogenetically defined low-risk AML, in particular those exhibiting an inv(16), can identify those with an increased risk of relapse who would then qualify for allogeneic HSCT. 55 In addition, the most frequent genetic aberration in AML (the NPM1 mutation) can be monitored quantitatively, enabling the identification of patients with an increased risk of relapse for whom allogeneic HSCT might be considered. 56, 57 These studies have consistently suggested that samples taken during treatment from bone marrow might be preferred over samples from peripheral blood and that a frequency of monthly monitoring during the first 6 months after the completion of treatment, and every 3-4 months thereafter, should be adhered to. 55, 57 Prediction of nonrelapse mortality
In general, nonrelapse mortality associated with myeloablative allogeneic HSCT is thought to outweigh the beneficial effect on relapse in patients with a cytogenetically favourable-risk profile. However, with the advent of reduced-intensity conditioning regimens as well the identification of the most important parameters that predict nonrelapse mortality, a careful assessment of the risk of nonrelapse mortality should complement the cytogenetic and molecular inventory of the risks associated with the leukaemia in each patient. The HOVON analysis of allogeneic HSCT using sibling donors in four large studies in patients with AML showed that age significantly predicted outcome (53% overall survival in patients <40 years versus 45% in patients >40 years, P <0.001), 5 a difference that was mainly contributed by increased nonrelapse mortality in patients who were >40 years in age. Apart from age, other variables that include general performance, cytomegalovirus serostatus, cytokine polymorphism, donor-recipient gender combination and comorbidities significantly predict for nonrelapse mortality (Table 2) . 58 Taking important indivi dual risk factors into account, composite risk scores were developed, including the European Group for Blood and Marrow Transplantation (EBMT) risk score and the haematopoietic cell transplantation comorbidity index (HCT-CI).
The EBMT risk score is based on five criteria: disease stage, patient age, donor type, time interval from diagnosis to transplantation and donor-recipient gender combination. 59 The score was developed in patients with chronic myleoid leukaemia and confirmed in several indepen dent patient cohorts. Furthermore, the score was tested and validated in other haemato logical disorders, including AML. 60 Patients with AML in their first complete remission who are receiving myeloablative allogeneic HSCT with a low EBMT risk score (between 0 and 1) experienced a nonrelapse mortality rate of <15%; patients with scores of 2-3 experienced a nonrelapse mortality rate of approximately 20-25%; patients with elevated scores (>4) showed enhanced nonrelapse mortality of approximately 35% (Figure 2a) . The EBMT risk score was initially conceived to assess nonrelapse mortality and survival. However, the score also demonstrated the ability to assess death from relapse. The observed reduction of overall survival in patients with increased scores was attributable to both enhanced nonrelapse mortality and an increased relapse rate. 59, 60 Despite this limitation, application of the score in the risk assessment of patients prior to transplantation is clinically useful and quite widely accepted. 61 Risk assessment for an individual patient is inherently complicated because, apart from pretransplant para meters, [58] [59] [60] [61] [62] peritransplant and post-transplant factors influence outcome (Table 2) . Peritransplant factors include the transplant techniques, conditioning regimen, graft-versus-hostdisease (GVHD) prevention measures used and the stem-cell source. 63 Post-transplant risk factors predominantly include GVHD, which needs to be assessed in terms of its own predisposing risks. 64 Pretransplant risk factors generally exert additive effects, but these can vary and depend on the sum of the risks. Survival is generally 3-5% worse for cytomegalovirus seropositive patients than seronegative patients, an effect that is especi ally evident in patients with low EBMT scores. 60 These findings illustrate that in addition to the EBMT score, cytomegalovirus status should be taken into account. By contrast, the role of the Karnofsky performance score might become increasingly important with increased EBMT risk scores, but is indepen dent from the effects of any comorbidities present. 65 Cytokine polymorphisms and single nucleotide changes within the HLA locus have been described as factors associated with outcome, which might be integrated in risk assessment in the future. 66 Another composite risk score is the HCT-CI, which was developed in Seattle, WA, USA. In earlier studies, the adapted Charlson Comorbidity Index predicted nonrelapse mortality, but the index lacked sensitivity. 67, 68 Thus, the more sensitive HCT-CI was developed based on a number of comorbidities. or 2 points resulted in a 2-year nonrelapse mortality rate of approximately 10%, 15-20% and 25%, respectively. A higher HCT-CI score of 3 or ≥4 resulted in nonrelapse mortality rates of 35-40% (Table 3) . A validation study showed the influence of the HCT-CI score on overall survival, nonrelapse mortality and relapse-free survival in patients with either AML or myelodysplastic syndrome. 71 The usefulness of the HCT-CI was subsequently also confirmed in other institutions, in patients with different diagnoses and in recipients of reduced-intensity conditioning prior to allogeneic HSCT, although these studies were retrospective and conducted in patients eligible for transplantation according to local policies. [72] [73] [74] [75] Another study in Spain also confirmed the score, but added more detail (Table 3) in patients with higher scores, which enabled the identification of subgroups of patients with a score >3. 76 Collectively, these studies suggest that acceptable rates of nonrelapse mortality following allogeneic HSCT can be expected in patients with a low EBMT score and/or with a low HCT-CI score. Accordingly, by combining the risk of relapse and nonrelapse mortality (Table 4 , Figure 1) , it can be argued that patients whose AML is characterized by a relapse risk >50% (which might be reduced to <25% after allogeneic HSCT) and for whom nonrelapse mortality can be estimated <25%, can be expected to benefit from allogeneic HSCT by a difference in DFS of at least 10% and, therefore, might qualify for allogeneic HSCT. Similarly, a nonrelapse mortality of approximately 30% may still be acceptable in patients whose leukaemia is characterized by a very high risk of relapse (>80% , Table 4 ).
Additionally, we would like to stress that transplant outcome continues to improve as a result of a number of developments. [77] [78] [79] [80] [81] These developments include improved supportive care, quality management systems, increasingly efficacious infection prophylaxis and safer conditioning prior to transplantation-such as the use of intravenous busulfan, which is preferable to the oral formu lation because of better bioavailability. 82, 83 Frequently applied and validated conditioning regimens in the myeloablative setting currently include the combination of cyclophosphamide and total body irradiation (TBI), or the combination of busulfan and cyclophosphamide. Reduced-intensity conditioning (RIC) regimens include combinations of fludarabine and low-dose TBI or fludarabine combined with intravenous busulfan. 84, 85 Thus, a number of developments have improved transplant outcome after both myeloablative and RIC prior to allogeneic HSCT, which necessitate repeated validation and refinement of nonrelapse mortality risk scores.
Application of alternative donors
Nonrelapse mortality following myeloablative allogeneic HSCT using an unrelated donor might still be somewhat higher than nonrelapse mortality following transplantation with cells from a sibling donor. However, high-resolution HLA typing has considerably improved donor-recipient matching and, thereby, outcome. 80 Nevertheless, the risk of nonrelapse mortality progressively increases with the number of HLA disparities, emphasizing the importance of high-resolution HLA typing and the selection of donors with, preferably, no more than one mismatched allele out of eight. 86, 87 Currently, a number of cooperative groups have incorporated unrelated donors into their allogeneic HSCT protocols for first-line treatment of patients with AML. This decision is based on multiple retrospective and prospective studies that have shown that 'well-matched' (eight out of eight alleles) unrelated donor grafts might be associated with acceptable rates of nonrelapse mortality and strong reductions of relapse in patients with AML in their first complete remission.
29, [88] [89] [90] [91] [92] [93] [94] For example, a prospective study of the German-Austrian AML Study Group showed equivalent efficacy and nonrelapse mortal ity in a head-to-head comparison of matched related and matched unrelated donors in adult patients with high-risk profiles who underwent allogeneic HSCT. 29 Collectively, these studies suggest that a transplant using a graft from an unrelated donor is justified if the a priori risk of relapse is sufficiently high and the risk of nonrelapse mortality following transplant is moderate. Given the time needed to identify and prepare for a transplant, the search for a sibling and the subsequent search for an unrelated donor should be performed as soon as possible after diagnosis and initial risk assessment.
Although the probability of identifying an adult unrelated donor can be as high as 60-80% for white patients, a considerable number of patients from other ethnic backgrounds struggle to find a suitable donor. Alternative donors and/or stem-cell sources include unrelated umbilical cord blood and haploidentical family donors. [95] [96] [97] [98] [99] [100] The extension of cord blood banks and the inclusion of their tissue type in the Bone Marrow Donors Worldwide file database has greatly facilitated the use of unrelated cord blood for allogeneic HSCT. Although the overall low cell dose initially hampered the develop ment of cord blood transplants in adult patients, results of comparative studies suggest that outcome after unrelated umbilical cord blood transplant might approach the results of unrelated bone marrow transplantation in acute leukaemia. 95, 96 Moreover, new developments-such as the use of double cord blood grafts and/or RIC-suggest that nonrelapse mortality following cord blood transplants can be reduced considerably. [97] [98] [99] Alternatively, patients with AML who lack a sibling or unrelated donor as well as cord blood, but who are transplant candidates, might benefit from a familial mismatched donor. 100 Haploidentical allogeneic HSCT exerts antileukaemic activity by an intensified preparatory regimen in combination with the possibility of donor-versus-recipient natural-killer-cell alloreactivity. Transplantation with either cord blood or haploidentical familial donors offers the advantage of immediate availability, which compares favourably with the 2-3-month time period needed to identify and prepare for a transplant using a graft from a matched unrelated adult donor. Currently, many centres do not routinely perform such transplants in patients with AML in their first complete remission because of the increased risk of nonrelapse mortality associated with these donors and stem-cell sources. However, patients in their first remission who have a very high risk of relapse (>80%) and who lack a matched (related or unrelated) donor might qualify for an alternative donor if the risk of nonrelapse mortality is estimated at <35%. Preferably, such transplants should be performed in experienced centres that have validated these transplants with respect to nonrelapse mortality and antileukaemic efficacy.
Reduced intensity conditioning
Although allogeneic HSCT has predominantly been studied in younger patients with AML <60 years in age, AML predominantly affects older individuals (median age at diagnosis of 71 years).
8 Nonmyeloablative or RIC regimens have been developed to reduce nonrelapse mortality in older or medically unfit patients who cannot tolerate myeloablative conditioning. Several studies have indeed shown that the morbidity and mortality following RIC allogeneic HSCT preceded by RIC are lower than with myeloablative conditioning, and that encouraging GVL effects are exerted (Figure 2b) . [101] [102] [103] Thus far, no mature results from prospective randomized studies comparing these two conditioning modalities have been reported in the literature. Most comparative studies have been performed retrospectively and concerned patients with AML or myelodysplastic syndrome in their first or second complete remission, or with advanced-stage disease. [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] During the prospective German-Austrian study, a growing number of patients received RIC regimens. 29 Although not randomized, this prospective study suggested equivalent results in patients receiving RIC or myeloablative regimens in terms of relapse, nonrelapse mortality and survival. 29 However, several retro spective studies have suggested a somewhat higher relapse rate in recipients of RIC and nonmyeloablative regimens preceding transplantation than in those receiving myeloablative conditioning. 105, [113] [114] [115] Notably, these studies relate to patients receiving different types of preceding induction and consolidation therapy, which might influence the outcome of allogeneic HSCT. Thus, prospective comparative studies in similarly pretreated patients are needed, including prospective randomized studies or prospective nonrandomized studies using allogeneic HSCT as a time-dependent covariate. 17, 20, 24 Nevertheless, prospective comparisons of older patients with AML by donor availability suggested improved DFS for patients with a donor. [116] [117] [118] In addition, two large retrospective studies in older cohorts of patients with AML also suggested improved outcomes in recipients of RIC compared with conventional chemo therapy. 119, 120 Ideally, a prospective randomized comparison of allogeneic HSCT from sibling or un related donors with chemotherapy as consolidation therapy should establish the long-term value of this approach, especially in older patients (Figure 1) . Currently, such a prospective randomized study is being performed in Europe by the EBMT and several cooperative groups.
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Late adverse effects (>2 years)
The decision whether or not to advise allogeneic HSCT as consolidation therapy has been discussed by considering the counterbalancing risks of relapse against the risk of nonrelapse mortality. Although this discussion is underpinned by mature survival data from a number of studies, late and persistent morbidity and quality-of-life data were not taken into account. These issues cannot be disregarded-especially when chemotherapeutic approaches and/or autologous HSCT, which are associated with reduced morbidity, continue to improve outcomes in patients with intermediate-risk AML profiles. [15] [16] [17] [18] Several studies have addressed the issue of late morbidity and late mortality occurring in recipients of allogeneic HSCT who were alive and well at 2 years post-transplantation. [122] [123] [124] [125] [126] A relative increase of 20% mortality, gradually occurring during the ensuing two decades after allogeneic HSCT, has been reported when comparing transplant recipients with age-matched controls. Late-onset morbidities can include long-lasting immune deficiency, endocrine dysfunction, skeletal disorders, ocular problems, respiratory tract problems, salivary gland dysfunction, dental problems, liver complications, vascular complications, chronic kidney disease, sexual dysfunction and secondary cancers. [127] [128] [129] [130] [131] All these conditions can adversely affect quality of life compared with adverse effects of conventional chemotherapy, which are usually transient. 131 Although a detailed discussion of late morbidities and the accompanying reduced quality of life goes beyond the scope of this article, we must stress that the major risk factor for most (if not all) these conditions is chronic GVHD and the long-term immuno suppressive therapy needed for its treatment. Steroids remain the standard initial treatment for GVHD, and, although many other approaches are currently available, most of the studies examining their use were retro spective or small phase I or II studies. 132 Preventive measures for GVHD include various immuno suppressive regimens given around the time of transplantation as well as the possible use of T-cell depletion (TCD) therapy. [133] [134] [135] Although efficacious, to what extent the various methods of TCD reduce the desired GVL effects is unclear, as is whether donor lymphocyte infusions at later time points post-transplantation entirely compensate for the loss. 135 However, the probability of chronic GVHD following non-TCD treatment in patients who underwent RIC before allogeneic HSCT is considerable; thus, a reliable risk estimate that predicts chronic GVHD is strongly needed. 136 A large study from Seattle estimated the most important risk factors of persistent GVHD were increased age, peripheral blood being the stem-cell source for the graft, use of stem cells from an unrelated donor and gender combination (for example, a female donor to a male patient). 137 Although a reduction of quality of life can also be incorporated quantitatively in the 'quality of life adjusted life years saved' measure, 138 the complicated quantifications can be extremely difficult to convey and discuss with individual patients, who might value the quality of his or her life on a very individual, personal basis. Thus, although composite risk scores for nonrelapse mortality are currently available, similar scores predicting for persistent GVHD and/or late morbidities are currently lacking, but are highly desirable.
Transplantation in second remission
Allogeneic HSCT has, because of its potent antileukaemic effects, consistently been considered the treatment of choice for most patients with AML who have relapsed. Outcomes of allografts beyond first remission, however, are inferior to those in patients in their first remission because of an increase in both treatmentrelated mortality (25-35%) and relapse (40-45%) rates. Breems et al. 139 reported a prognostic index-based on a cohort of 667 patients-for adult patients with AML who have relapsed. Four relevant parameters significantly predicted for outcome-length of the relapse-free interval, age at relapse, cytogenetics at diagnosis and whether or not patients had received a previous transplantation. On the basis of these parameters, three risk groups could be defined. In all three groups, recipients of an allogeneic HSCT faired better than patients treated with chemotherapy or an autograft. However, only 249 of 667 (37%) patients entered a second complete remission and fewer than 50% of those patients proceeded to allografting (n = 109), indicating that, ultimately, only 16% of patients who relapsed received the preferred treatment option. 139 Subsequent observations were reported by Kurosawa et al. 140 and by Armistead et al., 141 who detailed results from 599 patients who had relapsed. These studies confirmed the beneficial effect of allogeneic HSCT, especially in patients achieving second remission. In addition, age, adverse cytogenetic markers and duration of first complete remission were again identified as important parameters. Given the restricted application of allogeneic HSCT to patients in second remission and the dismal outcome in patients who did not proceed to allogeneic HSCT, allografting should, therefore, preferentially be considered for patients in their first remission.
Patients who do not achieve remission after one or two courses of chemo therapy, including high-dose cytosine arabinoside, usually have a dismal prognosis. Phase II studies have suggested that allogeneic HSCT might rescue some of these patients, as noted by DFS rates of 15-40%. 142 Schmid et al. 143 reported fairly favourable results in patients with primary refractory AML after allogeneic HSCT using an RIC regimen, preceded by a course of chemotherapy with fludarabine, amsacrine and cytarabine. Out of 103 patients with refractory AML with a median age of 52 years, 91% achieved a complete remission. Although encouraging, the group of patients included some individuals who might have achieved a second remission upon regular reinduction chemotherapy, and hence might have achieved remission upon ongoing chemotherapy. Nevertheless, this observation needs further confirmation and suggests that early timing of allogeneic HSCT in patients with AML in primary induction failure might be crucial to improve results.
